Oncolytic viruses (OVs) are promising therapeutic agents for cancer treatment, with recent studies emphasizing the combined use of chemotherapeutic compounds and prodrug suicide gene strategies to improve OV efficacy. In the present study, the synergistic activity of recombinant vesicular stomatitis virus (VSV)-MD51 virus expressing the cytosine deaminase/uracil phosphoribosyltransferase (CD::UPRT) suicide gene and 5-fluorocytosine (5FC) prodrug was investigated in triggering tumor cell oncolysis. In a panel of VSV-sensitive and -resistant cells-prostate PC3, breast MCF7 and TSA, B-lymphoma Karpas and melanoma B16-F10-the combination treatment increased killing of non-infected bystander cells in vitro via the release of 5FC toxic derivatives. In addition, we showed a synergistic effect on cancer cell killing with VSV-MD51 and the active form of the drug 5-fluorouracil. Furthermore, by monitoring VSV replication at the tumor site and maximizing 5FC bioavailability, we optimized the treatment regimen and improved survival of animals bearing TSA mammary adenocarcinoma. Altogether, this study emphasizes the potency of the VSV-CD::UPRT and 5FC combination, and demonstrates the necessity of optimizing each step of a multicomponent therapy to design efficient treatment.
Introduction
Targeted cancer therapy using oncolytic viruses (OVs) is an experimental therapeutic approach that is now supported by promising preclinical and clinical advances. 1, 2 OVs exploit genetic abnormalities and altered signaling pathways in tumor cells to achieve selective virus replication and tumor cell lysis. 3 Vesicular Stomatitis Virus (VSV) is a negative single-stranded RNA virus that has served as an important prototype OV. VSV is exquisitely sensitive to type 1 interferon-mediated antiviral responses in untransformed cells, and consequently its selective oncotropism is attributed to the innate antiviral response suppression in tumor cells. [4] [5] [6] [7] Although successful tumor eradication and tumor growth delay have been reported in animal models following treatment with OVs, several cancer models remain partially or completely resistant to viral oncolysis. Barriers to effective tumor oncolysis include intrinsic resistance of tumor cells to infection, limited tumor cell death induced by direct viral replication and inefficient viral spreading within the tumor mass. 8 To overcome these barriers to oncolysis, experimental strategies are now combining OVs with different cytotoxic agents to generate a synergistic effect between the OV and the chemotherapeutic compound that augment tumor cell killing. VSV has been used in combination with chemotherapeutic agents such as histone deacetylase inhibitors, BCL-2 inhibitors, rapamycin, doxorubicin and other compounds to enhance therapeutic activity. [9] [10] [11] [12] Limitations arising from the use of chemotherapeutic agents include non-selective toxicity in healthy tissues and development of drug resistance. One way to circumvent these restrictions and to further utilize OV combinations is to incorporate a suicide gene strategy that allows specific gene transduction of tumor cells with nonmammalian enzymes that convert innocuous prodrugs into highly toxic chemotherapeutic compounds within the tumor. 13 VSV represents an excellent choice as a vector for suicide gene transduction because of selective cancer cell tropism and the relative ease of foreign gene insertion. 4, 5, 14 VSV engineered to express suicide enzymes allow the conversion of non-toxic prodrug into a toxic form only at the site of viral replication, thus generating specific bystander killing at the tumor site. Recombinant VSV carrying the Herpes virus TK enzyme has been shown to phosphorylate the non-toxic prodrug ganciclovir, facilitating its DNA integration and subsequent local toxicity. 13, 15 A similar strategy was employed with VSV expressing the human sodium iodine symporter that resulted in the accumulation of radioactive iodine at the tumor site. 16 Both of these recombinant VSV strategies were shown to delay tumor growth in murine models; however, their action is restricted to cells that are directly infected by VSV.
One of the most potent suicide gene strategies involves local expression of the fusion enzyme cytosine deaminase/ uracil phosphoribosyltransferase (CD::UPRT) and the systemic delivery of the non-toxic 5-fluorocytosine (5FC). CD::UPRT enzyme is the fusion of Escherichia coli CD and uracil UPRT; CD catalyzes the deamination of the non-toxic 5FC into the commonly used chemotherapeutic 5-fluorouracil (5FU). The 5FU undergoes further enzymatic conversion by mammalian enzymes to form toxic derivatives that incorporate into DNA and RNA, and inhibits thymidylate synthetase enzymatic activity. The UPRT enzyme bypasses some rate-limiting mammalian enzymatic steps in the conversion of 5FU and therefore increases its toxicity. The high solubility of 5FU promotes a strong bystander effect on neighboring tumor cells that are not actively infected, which confers an important advantage to this combination compared with other suicide gene strategies. 13, 17 The CD::UPRT-5FC system is thus a powerful tool for cancer therapy, including oncolytic experimental strategies. [18] [19] [20] [21] [22] In addition to these suicide gene approaches, VSV variants that possess increased oncolytic potential compared with wild-type VSV have been characterized. The methionine 51 deletion in the matrix gene (VSV-MD51) is the best-characterized and probably the most potent variant. 6 Because of the altered M protein, VSV-MD51 no longer blocks the nuclear export of host RNA encoding antiviral proteins, including multiple species of interferons, and thus triggers a stronger interferon response in normal tissues that inhibits VSV infection, whereas VSV replication in interferon-defective tumor cells is not altered. 4, 6, 23, 24 In the present study we merged the attributes of VSV-MD51 with the CD::UPRT/5FC suicide gene system and further improved the previously reported VSV-CD::UPRT strategy. 22 Recombinant VSV-MD51 engineered to express CD::UPRT in combination with 5FC increased cancer cell killing in vitro in VSV-resistant cell lines and in a viral dissemination blocking model. In addition, a synergism between VSV oncolysis and 5FU chemotherapeutic killing was observed. Furthermore, to improve the in vivo efficacy of the combination, we coordinated the kinetics of VSV replication within the tumor with 5FC bioavailability, and obtained stronger therapeutic effect in a syngeneic tumor model.
Materials and methods
Cell lines and viral production MCF7 human breast cancer, B16-F10 mouse melanoma and Vero cell lines were cultured as recommended by ATCC (Manassas, VA). TSA mammary adenocarcinoma cells were a kind gift from Dr Barber (University of Miami, Miami, FL) and were grown as previously described. 25 Karpas-422 cells were purchased from German Collection of Microorganisms (Braunschweig, Germany) and were grown in RPMI 1640 medium with 10% fetal bovine serum. EG7 mouse T-cell lymphomas were a kind gift from Dr Galipeau (McGill University, Montreal, Canada) and were grown in RPMI 1640 medium with 10% fetal bovine serum and 0.5 mg ml À1 of G418. Virus stocks were grown in Vero cells, concentrated from cell-free supernatants by centrifugation and titrated by standard plaque assay as previously described. 10, 26 Viruses and construction of recombinant VSV To create VSV-C, the CD::UPRT E. coli fusion enzyme was amplified from a derivative plasmid (kindly provided by Dr Bernard Massie, NRC Biotechnology Research Institute, Montreal, QC) containing CodA::upp gene (Invivogen, San Diego, CA) using 5 0 -AAGGACTCGAG CCATGGTGTCGAATAACGCTTT-3 0 and 5 0 -ATTT CTCTAGACTTATTTCGTACCAAAGATTTTGTC-3 0 primers. Amplified product was digested with Xho1/Xba1 and ligated into the Xho1/Nhe1 unique site between the G and L viral genes of the VSV genome-expressing vector harboring the methionine 51 deletion in the M-coding sequence. 6 Infectious recombinant VSV was recovered as described previously.
14 VSV-GFP and VSV-Luc are recombinant VSV-MD51 containing green fluorescent protein (GFP) or GFP::Firefly Luciferase gene insertion between the G and L viral genes and were kindly provided by Dr John Bell (Ottawa Cancer Centre, Ottawa, ON).
CD::UPRT enzymatic assay
The 5-Fluorocytosine (Sigma, Saint Louis, MO) conversion into 5FU and derivatives was measured by spectrophotometry, and calculations were performed as previously described. 27 The 5FC conversion was measured using cell lysate from MCF7 cells infected for 24 h with 0.1 multiplicity of infection (MOI) in phosphatebuffered saline (PBS) containing 3 mM 5FC; alternatively, conversion was measured directly in 5FC-supplemented media of infected cells.
Measurement of bystander killing by CD::UPRT/5FC VSV-sensitive MCF7 cells were infected at 0.1 MOI, with or without 3 mM 5FC, into the culture media for 24 or 48 h. CD::UPRT enzymatic activity was measured and supernatants were heat inactivated at 65 1C for 20 min. MCF7 cells were plated in 96-well plates, and various dilutions of infected supernatant were then added. Cell viability was monitored at 48 h later by 3-(4,5-dimethylthiazol)-2,5-diphenyl tetrazolium (MTT) dye absorbance according to the manufacturer's instructions (Chemicon, Billerica, MA). In the second experimental set up, TSA cells were seeded into 6-well plates; 0.02 mM Anapore membrane cell culture insert (NUNC, Rochester, NY) was then placed into each well, and TSA cells were also seeded in the top chamber. Medium was either supplemented or not with 3 mM 5FC, and the upper-chamber cell population was infected with VSV-C at 0.1 MOI. At 48 h, viability in the lower chamber was monitored by flow cytometry on a FACSCalibur (Becton Dickinson, Franklin Lakes, NJ) after staining with propidium iodide (PI) and AnnexinV-APC (BD biosciences, Franklin Lakes, NJ). FACS analysis was performed with FCS Express version 3 (De Novo Software, Los Angeles, CA). For VSV-resistant cell lines (B16-F10, Karpas-422 and PC3), cells were infected with VSV-C at 10 MOI for Karpas-422 and B16-F10, and 0.1 MOI for PC3. For some conditions, 3 mM of 5FC was added, and cell viability was monitored at 96 h by flow cytometry using AnnexinV/PI staining.
VSV and 5FU combination and synergism Karpas-422 and PC3 cells were treated with 375 uM of 5FU (Sigma) and infected with VSV-MD51 (harboring no insertion) at 10 and 0.1 MOI, respectively. Cell viability was assessed by MTT assay at 48 h later, and data were used to determine combination index using Calcusyn program (Biosoft, GB, UK). Similar combination index values were obtained when cell viability was monitor by AnnexinV/PI staining (data not shown). To evaluate VSV replication in the presence of 5FU, TSA cells were pretreated with 0. ) were subcutaneously injected into the flank of 8-week old female Balb/c or C57Bl/6 mice, respectively; 7 days after inoculation, tumors were palpable and treatment was started. To monitor the presence of VSV at the tumor, two intratumoral injection of VSV-Luc (2 Â 10 7 plaque-forming units (PFUs)) were administered on days 0 and 3. Two mice were killed every day for 8 days, and tumors were weighed and snap frozen. Tumors were homogenized in 500 ul of PBS using a Polytron PT1200 homogenizer (Kinematica, Bohemia, NY), and virus titration was performed. To measure luciferase activity, tumor homogenate were frozen and thawed twice before they were used for luciferase reporter assays (Promega Corporation, Madison, WI) according to the manufacturer's instructions using a GLIOMAX 20/20 luminometer (Promega Corporation). To evaluate the toxicity of the adapted 5FC-dosing schedule, 5FC was diluted in PBS, and Balb/c mice received intraperitoneal injections of 500 mg kg À1 every 160 min, four times per day over a period of 4 days; control mice were injected with PBS (n ¼ 4). For tumor volume and survival experiments, TSA tumors were established as described above and mice were treated with two doses of 2 Â 10 7 PFU of VSV-C, VSV or heat-inactivated VSV (HI-VSV) intratumorally on days 0 and 3. Mice injected with VSV-C or HI-VSV received intraperitoneal injection of 5FC corresponding to 500 mg kg À1 every 160 min, four times per day over a period of 4 days. Tumor size was measured using a caliper, and tumor volume was calculated using the formula: length Â width 2 /2. Mice were killed when tumor volume reached 1500 mm 3 . Unpaired t-test and log-rank statistical analyses were performed on growth curve and Kaplan-Meier survival graph using Prism 4 (GraphPad, San Diego, CA).
Results
Generation and characterization of VSV expressing CD::UPRT enzyme VSV-MD51 was genetically modified to express the E. coli fusion enzyme CD::UPRT (VSV-C) by inserting the gene cassette between the G-and L-coding regions of the VSV-MD51 genome vector (Figure 1a) . To confirm that the insertion did not affect viral replication, the growth rate of the resulting recombinant VSV was determined and was similar to VSV-MD51 without gene insertion (Figure 1b) . To assure the expression and functionality of the CD::UPRT fusion enzyme, a spectrophotometric enzymatic assay was used to measure 5FC prodrug conversion into 5FU and downstream products. VSV-C infected cell lysates contained functional enzyme that allowed degradation of 5FC into its active 5FU cytotoxic derivatives, whereas uninfected or VSV-MD51-infected cell lysates did not show degradation of 5FC (Figure 1c) .
VSV-C/5FC combination results in bystander cell killing in vitro
Having confirmed functional expression of the transgene, we next examined whether the combination approach Improving VSV-CD::UPRT suicide gene combination S Leveille et al would increase bystander cell killing. In VSV-sensitive cell lines, viral lysis occurs rapidly, and death of all cells is normally achieved within 48 h. In these cells, killing induced exclusively by 5FU and its cytotoxic derivatives cannot be measured directly in vitro and the two eventsdirect VSV cell lysis and cytotoxicity of 5FU following 5FC conversion-must be separated. Events were initially separated in time as previously reported. 22 VSV-sensitive MCF7 cells were infected with VSV-C for 24 h in the presence of 5FC. Conversion of 5FC into 5FU and downstream products reached 39 and 90% at 24 and 48 h, respectively (data not shown). Supernatants were collected, heat-inactivated to destroy the virus, diluted and added to freshly plated MCF7 cells for 48 h before cell viability was monitored. The toxic effect of 5FU derivatives, converted during VSV-C replication, was observed with supernatants diluted up to 250 fold. Supernatants from non-infected cells supplemented with 5FC did not result in cell killing, confirming that 5FC does not cause cytotoxicity and is not spontaneously converted. In addition, cell death by any remaining infectious virus after heat inactivation was not a contributing factor, as infected supernatants did not affect cell viability in the absence of 5FC (Figure 2a ). An additional experimental model in which infected cells were separated from non-infected cells was developed to mimic a tumor environment where only a portion of the cells are actively infected by VSV. Murine TSA mammary adenocarcinoma cells were plated in transwell chambers separated by a 0.02 mM membrane that allowed free diffusion of drugs while blocking passage of virions. On one side of the chamber, cells were infected with VSV-C in the presence of 5FC. At 48 h, the cell population infected with VSV-C in the presence of 5FC reduced the viability of the population on the other side of the transwell to 28%, whereas the absence of either VSV-C or 5FC did not reduce cell viability of the second population (Figure 2b) . Thus, in a tumor environment, cancer cells actively infected with VSV-C in the presence of 5FC are able to drive cell death of non-infected surrounding tumor cells by the diffuse chemotherapeutic action of 5FU.
VSV-C/5FC increases the spectrum of cancer cell killing
To further demonstrate the increased therapeutic potential of the combination, the efficacy of the VSV-C/5FC combination was examined in cancer cell lines that are resistant to VSV oncolysis and restrict virus replication, even at high MOI. In these cell lines, VSV does not lead to massive cell lysis and therefore 5FU-mediated cell killing could be directly measured. Karpas, human B-lymphoma; B16-F10, mouse melanoma; and PC3, human prostate cancer cell lines were infected with VSV-C in the presence of 5FC. In all three cell lines, despite the limited number of infected cells, the conversion of 5FC to 5FU and its derivatives significantly decreased cell viability compared with VSV treatment alone: 72-36%, 73-41% and 50-27%, respectively (Figure 2c ). Thus the VSV-C/5FC prodrug combination expands the spectrum of tumor cells that can be targeted using VSV by promoting efficient cell killing through 5FC toxic derivative release.
VSV and 5FU have a synergistic effect on cancer cell killing Combination treatment leads to the simultaneous presence of VSV and 5FU within the tumor and therefore potentially affects two aspects of the treatment: cancer cell killing and viral replication. To determine the effect of the simultaneous presence of the two active agents on cancer cell killing, Karpas and PC3 cell lines (both VSV Improving VSV-CD::UPRT suicide gene combination S Leveille et al resistant), were incubated with 5FU and VSV-MD51 (harboring no gene insertion). As expected, VSV-MD51 treatment alone modestly reduced Karpas and PC3 cell viability to 70 and 57%, respectively, whereas 5FU treatment alone reduced survival to 48 and 38%, respectively. The combined treatment of VSV-MD51 and 5FU resulted in a dramatic reduction in tumor cell viability, with only 29% of Karpas and 24% of PC3 cells remaining alive (Figure 3a) . Cell viability results were used to calculate the combination index based on the method of Chou and Talalay, 28 and in both cell lines, the combination of 5FU and VSV-MD51 resulted in combination index values that revealed significant synergism (Figure 3b ). These data further highlight the advantage of the VSV-C/5FC combination, as the active form of the drug-which is only present at the site of the tumor-can synergize with VSV to enhance tumor cell killing. Second, the effect of 5FU on VSV replication was examined. At subeffective 5FU concentration, part of the cells survive 5FU treatment and the ability of VSV to replicate in these cells was evaluated. Murine TSA cells were pretreated with a subeffective concentration of 5FU for 24 h and then infected with VSV-GFP; living cells were discriminated from apoptotic cells by AnnexinV/PI staining, and expression of GFP in living cells was used as a marker of viral replication. At 1 MOI, VSV infected TSA cells at a similar rate, regardless of the presence of 5FU, whereas at 0.1 and 0.01 MOI, 5FU treatment delayed the onset of VSV replication, although VSV infection levels were restored by 24 h (Figure 3c ). Thus in a tumor environment, VSV replication may be slowed down but should not be blocked by the presence of 5FU.
Adapting the prodrug strategy to VSV-MD51 in vivo
The in vitro efficacy of the VSV-C/5FC combination prompted us to examine the parameters for in vivo treatment. VSV is an acutely replicating OV with a short replication cycle; it is rapidly cleared by the immune system and consequently its presence at the tumor is transient. 29, 30 To correlate the expression of the prodrugconverting enzyme with 5FC availability at the tumor site, VSV was monitored in two tumor models. Subcutaneous TSA mammary adenocarcinomas and E.G7 T-cell lymphomas were treated with two intratumoral doses of a VSV-MD51 expressing luciferase on day 0 and 3. In the TSA model, high virus titers were detected in the tumor homogenates during the first 3 days after injection but decreased thereafter until titers were below detection by day 6 (Figure 4a) . Although viral replication was higher in the E.G7 model compared with the TSA model, viral titers also drastically decreased at day 6 (Figure 4b ). Monitoring luciferase activity from the tumor homogenates also offered a relative measure of the time frame of CD::UPRT expression, as the luciferase gene was inserted into VSV genome at the same position as CD::UPRT. The relative light unit generated by luciferase expression was high during the first few days after inoculation but faded rapidly, although a second injection extended enzyme expression for an additional day in both tumor models (Figure 4b and d) . Altogether, these data indicate that VSV replication and gene expression at the tumor were high for a period of 3-4 days, but essentially disappeared by day 6. Thus in the VSV-C/5FC system, 5FC conversion would occur for B96 h after VSV injection.
Adapting the VSV-C/5FC strategy to 5FC bioavailability in vivo In previous reports, 5FC was administered to mice at 500 mg kg À1 per day intraperitoneally for 10 days. Meanwhile, other studies demonstrated that the half-life of 5FC was B40 min and that 5FC freely diffused into tissue, [31] [32] [33] suggesting that after 160 min (that is, four halflives), only 6% of the initial 5FC dose would be present at the tumor. Therefore, an adapted treatment regimen was designed to maximize the bioavailability of CD::UPRT enzyme at the tumor (Figure 5a ). To test the toxicity of the modified regimen, mice were injected with 500 mg kg À1 every 160 min, 4 times per day for 4 days. No sign of toxicity was observed, and animals did not suffer any weight loss compared with control animals treated with PBS (Figure 5b ).
19-22
The adapted VSV-C/5FC regimen improved therapeutic effect The efficacy of the adapted VSV-C/5FC regimen was tested in vivo in TSA tumor-bearing mice. The adapted combined treatment delayed the onset of tumor growth compared with VSV-MD51 treatment alone (P-value of 0.002; Figure 6a ). Furthermore, survival improved compared with VSV-MD51 treatment alone (P-value of 0.0006), with 3 out of 10 animals completely tumor free for 460 days after treatment (Figure 6b ). On the other hand, in animals inoculated with VSV-C and 500 mg kg per day of 5FC for 10 days, no significant delay in tumor growth and/or survival was observed compared with animals treated with VSV-MD51 alone (data not shown).
Altogether, these data demonstrate that increasing the frequency of 5FC administration to coordinate bioavailability of 5FC with acute VSV replication significantly improved the therapeutic effect of VSV-MD51. 
Discussion
The combination of CD::UPRT suicide gene expression and 5FC prodrug conversion-together with tumorspecific VSV oncolysis-represents a powerful experimental therapeutic approach, characterized by a dual tumor cell-killing effect. In the present study, we incorporated a potent oncolytic VSV variant (VSV-MD51) with the enzymatic activity of CD::UPRT that converts 5FC into the toxic 5FU. Building upon the previous report of VSV expressing this powerful suicide gene, we further demonstrated the potential of this strategy by exploring new approaches in vitro and more importantly by refining the therapy in vivo. By monitoring VSV replication at the tumor site and correlating these results with the bioavailability of 5FC, the modified treatment regimen improved survival of animals bearing TSA mammary adenocarcinoma subcutaneous tumors.
In vitro data demonstrated that a few infected cancer cells through the release of 5FU and other toxic derivatives synergistically increased cell killing of noninfected cells. Furthermore, the combination targeted tumor cells that are normally refractory to VSV oncolysis, thus potentially increasing the spectrum of cancer cells susceptible to VSV treatment. Given that higher tumor cell killing is achieved from fewer infected cells, it appear that tumor cell killing induced by the combination treatment in vivo would not be limited by direct virus replication, inefficient spread of virus or intrinsic resistance to oncolysis, therefore reinforcing the capacity of this approach to overcome several limitations to OV-mediated oncolysis. 8 Combination strategies using chemotherapeutic compounds and OVs simultaneously are designed to target and increase cancer cell killing, in part, by modulating the antiviral state of the tumor cell or by enhancing the capacity to stimulate apoptosis and/or cell cycle arrest. [9] [10] [11] [12] Histone deacetylase inhibitors or rapamycin have demonstrated enhanced effects on oncolysis, in part, through their capacity to increase OV replication, by dampening the innate antiviral response. 9, 11 Increased therapeutic effect has also been achieved under circumstances when viral replication and spreading are not enhanced. 10 Tumor cells encountering 5FU at subtoxic concentrations are altered metabolically by the drug; 34 such cellular changes could potentially affect OV permissiveness. The previous study 22 addressed this question by pretreating cells with 5FU for 24 h, removing the drug at the time of infection and monitoring viral GFP expression. No change in VSV replication was reported, although a 25% reduction in GFP-positive cells was observed at 12 h and a B7-fold reduction in viral titer at 24 h following infection at 0.1 MOI. We addressed this concern differently by using continuous 5FU treatment at concentrations corresponding to the ED50 over a period of 48 hwhich is necessary to allow 5FU cytotoxicity 34 -and by analyzing the susceptibility of the surviving cells to VSV. Although infection kinetics was slowed at low MOI, VSV was able to infect viable cells, indicating that 5FU did not affect viral infection. Although our data clearly demonstrated a synergistic effect on cancer cell killing between 5FU and VSV, the VSV-C/5FC combination and subsequent conversion to 5FU did not increase virus replication in cancer cells in vitro. Therefore, the beneficial effect of the VSV-C and 5FC combination in vivo resides in bystander killing of surrounding non-infected cells by 5FU and other toxic derivatives.
One of the important challenges of this study was to refine the in vivo VSV-C/5FC strategy to improve therapeutic outcome. The 5FC administration was modified to coincide with the peak of VSV replication within the tumor. Using two different subcutaneous syngenic tumor models-TSA, a VSV-resistant model where virus treatment causes only tumor growth delay, and E.G7, a VSV-sensitive model where VSV oncolysis cures the majority of the mice (SL unpublished data)-we demonstrated the transient nature of VSV kinetics at the tumor following two intratumoral injections, consistent with other studies in CT26 and B16OVA models. 29, 30 The acute pattern of VSV replication prompted us to reevaluate the timing of 5FC administration, to maximize CD::UPRT enzyme expression with 5FC bioavailability. Although previous studies with CD::UPRT suicide gene approaches reported a typical 5FC dosing of 500 mg kg À1 per day for 10 days, [18] [19] [20] [21] [22] transient VSV Figure 6 VSV-C and the adapted 5FC-dosing regimen increase animal survival. TSA mammary adenocarcinoma tumors were established by subcutaneous inoculation of 3 Â 10 5 cells; 7 days later when tumors were palpable, 2 Â 10 7 PFU of VSV-C, VSV or heat-inactivated VSV were injected intratumorally on day 0 and 3. The 5FC was administered by intraperitoneal injections corresponding to 500 mg kg À1 every 160 min, four times per day for a period of 4 days. (a) Tumor volume was monitored and (b) animal survival was recorded (n ¼ 10). Error bars represent the s.e.
Improving VSV-CD::UPRT suicide gene combination S Leveille et al replication and gene expression within the tumor indicated that this regimen was not optimal for a VSV-based therapy. Furthermore, studies evaluating 5FC bioavailability and half-life in serum and tissue highlighted a multiple-dose daily regimen. [31] [32] [33] Although increasing the administration frequency raises concerns about toxicity, 5FC has been used experimentally as an antifungal agent at doses up to 200 mg kg À1 every 6 h for 7 days without signs of toxicity. 35 The current regimen of 500 mg kg
À1
four times a day for 4 days did not reveal any signs of toxicity, and permitted a correlation between maximal 5FC bioavailability and high level expression of CD::UPRT at the tumor. The modified VSV/5FC prodrug combination inhibited tumor growth better than either treatment alone, and increased animal survival, relative to the previously published combination approach in the TSA syngenic tumor model. 22 These experiments emphasized the advantages of analyzing each step of a multicomponent therapy to optimize the treatment schedule and achieve maximal therapeutic benefit. In conclusion, this study further demonstrated the potential of an OV-suicide gene strategy for cancer therapy and highlighted the necessity to analyze different kinetic aspects to design the most effective treatment.
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